March 18, 2010
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Presurgical ovarian cancer blood test available, covered by Medicare
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The OVA1 blood test, a presurgical test to help assess whether an ovarian mass is malignant, is now available nationally and will be covered by Highmark Medicare Services.
The OVA1 test (Vermillion) is a protein-based in vitro diagnostic test that uses five biomarkers — prealbumin, apolipoprotein A-1, beta2-microglobulin, transferrin, and CA-125 — and proprietary software to produce a numeric result to help physicians determine whether a mass if malignant.
The test is indicated for women:
- Older than 18 years.
- With an ovarian mass for which surgery is planned.
- Who have not yet been referred to an oncologist.
The test is meant to be used in addition to a physician’s independent clinical and radiological evaluation, and is not a screening test.
 |
Follow HemOncToday.com on Twitter. |